Get the Stockscreener App
23.19
3.21%
-0.77
After Hours:
23.70
0.51
+2.20%
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 5.4%Time to Buy? - MarketBeat
Catalyst Pharmaceuticals stock hits all-time high of $24.44 - Investing.com
Is Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Simply Wall St
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Moody Aldrich Partners LLC Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Nilsine Partners LLC Purchases New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Pacer Advisors Inc. - MarketBeat
11,320 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Dakota Wealth Management - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.86 Consensus Target Price from Brokerages - MarketBeat
Charles B. O?Keeffe Decides to Not Stand for Reelection for Board At the 2025 Annual Meeting of Catalyst Pharmaceuticals, Inc - Marketscreener.com
Catalyst Pharmaceuticals board member to retire By Investing.com - Investing.com Canada
(CPRX) Investment Analysis - Stock Traders Daily
Catalyst Pharmaceuticals board member to retire - MSN
Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis - MarketBeat
Catalyst Pharma Announces Board Member’s Departure - TipRanks
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Receives Prestigious Ranking on - GlobeNewswire
FIRDAPSE now available in Japan for muscle weakness - MSN
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan - The Manila Times
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Up 12.5% in December - MarketBeat
Redhawk Wealth Advisors Inc. Takes $1.27 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to "Buy" at StockNews.com - MarketBeat
HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price - MarketBeat
Catalyst Settles Patent Fight Against Teva Over Firdapse - Law360
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva - MSN
Catalyst Pharmaceuticals' (CPRX) "Buy" Rating Reiterated at Bank of America - MarketBeat
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical - Yahoo Finance
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - MSN
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 13% HigherWhat's Next? - MarketBeat
Catalyst stock climbs 15% on Firdapse litigation settlement - MSN
Catalyst Pharma Gains, Teva Patent Settlement Seen Positive (1) - Bloomberg Law
Catalyst Pharmaceuticals Reaches Settlement With Teva in Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Reaches Settlement Deal With Teva Over Firdapse Patent Litigation - Marketscreener.com
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva - MarketWatch
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals - The Manila Times
Catalyst Pharmaceuticals reports settlement of Firdapse patent litigation with Teva - TipRanks
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® - GlobeNewswire
Catalyst Pharmaceuticals' (NASDAQ:CPRX) earnings growth rate lags the 37% CAGR delivered to shareholders - Simply Wall St
Oliver Luxxe Assets LLC Purchases 35,225 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Interesting CPRX Call Options For January 17th - Nasdaq
Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by StockNews.com to "Strong-Buy" Rating - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
(CPRX) Long Term Investment Analysis - Stock Traders Daily
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):